According to CAS Medical, the Fore-Sight cerebral oximeter is a near infra-red spectroscopy based device that non-invasively and continuously detects oxygen saturation changes in brain tissue, allowing clinicians to quickly react to reverse potentially harmful events before they become critical.
CAS Medical said that Fore-Sight is the first and only device that provides a non-trend, absolute measure of cerebral tissue oxygen saturation for all patient populations regardless of age and weight.
Andrew Kersey, president and CEO of CAS Medical Systems, said: "We are pleased with the FDA's decision to expand clearance for the Fore-Sight cerebral oximeter to include patients below 2.5kg. This expanded labeling will allow us additional access into the neonatal intensive care unit market, where a large percentage of at-risk patients have a low or very low birth weight.
"In conjunction with the unique benefits that the Fore-Sight small sensor offers - including Cool-Light technology that protects fragile skin from heat, non-adhesive sensor solutions, and a very small sensor footprint - the new, expanded labeling uniquely positions CAS Medical Systems for acceptance in the neonatal arena."
http://www.datamonitor.com
Republication or redistribution, including by framing or similar means, is expressly prohibited without prior written consent. Datamonitor shall not be liable for errors or delays in the content, or for any actions taken in reliance thereon

More News:
Market Updates |
Stock Alerts |
All Trading News |
Stock Index